Holen Sie sich die Stockscreener-App
6.03
2.58%
-0.16
Handel nachbörslich:
6.03
Schlusskurs vom Vortag:
$6.19
Offen:
$6.11
24-Stunden-Volumen:
59,549
Relative Volume:
0.58
Marktkapitalisierung:
$153.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.38M
KGV:
-4.2766
EPS:
-1.41
Netto-Cashflow:
$-15.54M
1W Leistung:
-1.31%
1M Leistung:
-2.11%
6M Leistung:
-38.34%
1J Leistung:
-6.51%
1-Tages-Spanne:
$5.93
$6.19
1-Wochen-Bereich:
$5.85
$6.30
52-Wochen-Spanne:
$4.44
$11.80
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Firmenname
Nuvectis Pharma Inc
Sektor
Branche
Telefon
360-837-7232
Adresse
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Vergleichen Sie NVCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
6.03 | 157.58M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Eingeleitet | Maxim Group | Buy |
| 2025-03-17 | Eingeleitet | Laidlaw | Buy |
| 2022-07-13 | Eingeleitet | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Aktie (NVCT) Neueste Nachrichten
Technical analysis overview for Nuvectis Pharma Inc. stockWeekly Trend Summary & Community Shared Stock Ideas - newser.com
Nuvectis Pharma Inc. stock trendline breakdownWeekly Volume Report & Community Shared Stock Ideas - newser.com
What data driven models say about Nuvectis Pharma Inc.’s future2025 Major Catalysts & High Conviction Trade Alerts - newser.com
Using RSI to spot recovery in Nuvectis Pharma Inc.Bond Market & AI Based Buy/Sell Signal Reports - newser.com
How strong is Nuvectis Pharma Inc. stock revenue growthJuly 2025 Big Picture & AI Optimized Trade Strategies - newser.com
Is Nuvectis Pharma Inc a good long term investmentEarnings Per Share Trends & Low Entry Investment Growth - earlytimes.in
Nuvectis Pharma (NASDAQ:NVCT) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Using flow based indicators on Nuvectis Pharma Inc.Oil Prices & Long-Term Growth Stock Strategies - newser.com
Applying Wyckoff theory to Nuvectis Pharma Inc. stockNew Guidance & Smart Allocation Stock Reports - newser.com
Published on: 2025-10-05 01:41:39 - newser.com
Price momentum metrics for Nuvectis Pharma Inc. explained2025 Key Lessons & Weekly Top Stock Performers List - newser.com
Using economic indicators to assess Nuvectis Pharma Inc. potential2025 Performance Recap & AI Powered Buy and Sell Recommendations - newser.com
How to use Fibonacci retracement on Nuvectis Pharma Inc.Market Growth Review & Low Drawdown Investment Ideas - newser.com
Momentum divergence signals in Nuvectis Pharma Inc. chartJuly 2025 Recap & Expert Approved Momentum Trade Ideas - newser.com
Using portfolio simulators with Nuvectis Pharma Inc. includedEarnings Growth Summary & Long-Term Safe Return Strategies - newser.com
Nuvectis Pharma Inc Stock Analysis and ForecastMarket Rumors and News & Market Trend Real-Time Reports - earlytimes.in
Goldman Sachs Group Inc. Takes $446,000 Position in Nuvectis Pharma, Inc. $NVCT - MarketBeat
What drives Nuvectis Pharma Inc stock priceTrading Volume Trends & Small Budget Trading Ideas - Early Times
Nuvectis Pharma (NASDAQ:NVCT) Shares Up 2.2% – Time to Buy? - Defense World
Nuvectis Pharma (NASDAQ:NVCT) Shares Up 2.2%Time to Buy? - MarketBeat
Nuvectis Pharma Appoints Juan Sanchez to Board - The Globe and Mail
Nuvectis Pharma adds former Intra-Cellular exec to board of directors - Investing.com Nigeria
Nuvectis Pharma adds former Intra-Cellular exec to board of directors By Investing.com - Investing.com South Africa
Nuvectis Pharma Appoints Juan Sanchez, MD, To Board - citybiz
Finanzdaten der Nuvectis Pharma Inc-Aktie (NVCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nuvectis Pharma Inc-Aktie (NVCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mosseri Marlio Charles | 10% Owner |
Jun 18 '25 |
Buy |
8.05 |
28,043 |
225,746 |
2,976,203 |
| Mosseri Marlio Charles | 10% Owner |
Jun 17 '25 |
Buy |
8.11 |
5,399 |
43,786 |
2,948,160 |
| Mosseri Marlio Charles | 10% Owner |
May 12 '25 |
Buy |
8.11 |
21,167 |
171,664 |
2,942,761 |
| Mosseri Marlio Charles | 10% Owner |
May 06 '25 |
Buy |
8.59 |
12,444 |
106,955 |
2,896,565 |
| Mosseri Marlio Charles | 10% Owner |
May 07 '25 |
Buy |
8.59 |
12,317 |
105,770 |
2,908,882 |
| Mosseri Marlio Charles | 10% Owner |
May 08 '25 |
Buy |
8.65 |
2,650 |
22,922 |
2,911,532 |
| Mosseri Marlio Charles | 10% Owner |
Feb 07 '25 |
Buy |
5.00 |
240,000 |
1,200,000 |
2,884,121 |
| BENTSUR RON | Chairman & CEO |
Dec 24 '24 |
Buy |
4.65 |
4,500 |
20,925 |
3,270,924 |
| Mosseri Marlio Charles | 10% Owner |
Dec 13 '24 |
Buy |
4.70 |
17,000 |
79,900 |
2,612,000 |
| Poradosu Enrique | Chief Science & Business Off |
Nov 19 '24 |
Buy |
4.99 |
2,000 |
9,980 |
1,506,319 |
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):